Document is current

Article History

Received: 9 August 2022

Accepted: 13 March 2023

First Online: 24 March 2023

Declarations

:

: The study protocol received ethical approval from Pearl IRB (Indianapolis, IN; IRB protocol # 22-BCGR-101). Respondents were provided background information on the intent of the study, and all provided written informed consent to participate. The study was conducted in accordance with the Declaration of Helsinki.

: Not applicable.

: George Dranitsaris has received consulting fees from Eisai Inc. Amir Tahami and Quanwu Zhang are employees of Eisai Inc. Lin Mu, Christopher Weyrer and Erik Dysdale are employees of the Boston Consulting Group. Over the last 5 years, Alireza Atri has received honoraria or support for consulting; participating in independent data safety monitoring boards; providing educational lectures, programs, and materials; or serving on advisory boards for AbbVie, Acadia, Allergan, the Alzheimer’s Association, Axovant, AZ Therapies, Biogen, Eisai, Grifols, Harvard Medical School Graduate Continuing Education, JOMDD, Lundbeck, Merck, Roche/Genentech, Novo Nordisk, Qynapse, Sunovion, Suven, and Synexus. Dr. Atri receives book royalties from Oxford University Press for a medical book on dementia. Dr. Atri receives institutional research grant/contract funding from NIA/NIH 1P30AG072980, AZ DHS CTR040636, Washington University St Louis, and Gates Ventures. Dr. Atri’s institution receives/received funding for clinical trial grants, contracts and projects from government, consortia, foundations and companies for which he serves/served as contracted site-PI, including for an Eisia-sponsored clinical trial (AHEAD 3–45). Dr. Atri did not receive funding, honoraria or support related to this study or manuscript.